Inclusion Criteria:

- Histologically documented Burkitt or atypical Burkitt according to World Health
Organization (WHO) criteria.

- Pathology must be reviewed at the Brigham and Women's Hospital (BWH).

- Measurable or evaluable disease: Disease reproducibly measurable in two perpendicular
dimensions on exam, computed tomography (CT), radiograph, or magnetic resonance
imaging (MRI). Disease present on bone marrow biopsy will be considered as evaluable
disease.

- The following may not be used as the sole site of measurable or evaluable disease:
*ascites, *pleural effusion, *bone lesion or *central nervous system (CNS) disease.

- Age > 18

- Laboratory data (within 2 weeks of study registration):

- ANC > 1500/ul;

- platelet > 100,000/ul;

- creatinine < 1.5 X normal;

- creatinine clearance > 60 ml/min;

- bilirubin < 1.5 X normal;

- AST and ALT < 2.5 X normal;

- alkaline phosphates < 3 X normal;

- HIV negative;

- cardiac ejection fraction > 50%.

Exclusion Criteria:

- Previous chemotherapy or radiation therapy. Steroids of less than 72 hours duration
for impending oncologic emergency are allowed.

- Uncontrolled bacterial, fungal, or viral infection.

- Concomitant malignancy excluding carcinoma in situ of the cervix and basal cell
carcinoma of the skin.

- Serious comorbid disease. Clinically significant pulmonary symptomatology. In
patients with a history of symptomatic pulmonary disease, pulmonary function tests
(PFTs) should document an forced expiratory volume at 1 second (FeV1), forced vital
capacity (FVC), and total lung capacity (TLC) of > 60% predicted and carbon monoxide
diffusing capacity of the lung (DLCO) of > 50% predicted. No clinically significant
cardiac symptomatology. The cardiac ejection fraction must be > 50%.

- Pregnancy. All males and females with reproductive potential must consent to use an
effective form of contraception while on study.

- Major surgery within the previous 2 weeks.